Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.53 |
| ▸ | CNR2 | P34972 | 1/20 | 0.53 |
| ▸ | LRRK2 | Q5S007 | 12/20 | 0.45 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4785792 | 0.82 | JAK2 (0.54) | CNR1CNR2AXLGSK3B | |
| SCHEMBL4783385 | 0.81 | ALDH1A1 (0.54) | CNR1CNR2LRRK2 | |
| SCHEMBL4225789 | 0.81 | MAPK1 (0.50) | CNR1CNR2LRRK2AXLGSK3B | |
| SCHEMBL4782452 | 0.78 | JAK2 (0.50) | CNR1CNR2AXLGSK3B | |
| SCHEMBL761105 | 0.77 | MAPK1 (0.54) | CNR1CNR2LRRK2AXLGSK3B | |
| SCHEMBL4783789 | 0.72 | AXL (0.38) | CNR1CNR2AXLGSK3B | |
| SCHEMBL4785556 | 0.71 | AXL (0.50) | AXL | |
| SCHEMBL30833725 | 0.71 | AXL (0.50) | AXL | |
| SCHEMBL4799096 | 0.70 | ALDH1A1 (0.46) | CNR1CNR2LRRK2 | |
| SCHEMBL22445950 | 0.69 | GSK3B (0.40) | CNR1CNR2AXLGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153810-A1 | INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-06-26 | — | — | US | disclosed |
| US-20080153810-A1 | INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-06-26 | — | — | US | disclosed |
| US-20080153810-A1 | INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-06-26 | — | — | US | disclosed |
| WO-2008061109-A2 | INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008061109-A2 | INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153810-A1 | INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS | MCHR1, MCHR2, MC1R | CNR1 179/4885CNR2 266/4885LRRK2 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.